Effect of eriodictyol on the development of atopic dermatitis-like lesions in ICR mice

Biol Pharm Bull. 2013;36(8):1375-9. doi: 10.1248/bpb.b13-00296.

Abstract

Atopic dermatitis (AD) is a chronic, allergic, and inflammatory skin disease associated with eczema and dermatitis symptoms. Our previous studies have reported that eriodictyol extract inhibits immunoglobulin E (IgE)/Ag-induced type I hypersensitivity by suppressing the activation of proinflammatory cytokines, such as interleukin-4 (IL-4), and the expression of ceramide kinase. In this study, we investigated the inhibitory effect of eriodictyol on 2,4-dinitrochlorobenzene (DNCB)-induced AD-like skin lesions in ICR mice. Treatment with 2 mg/mL eriodictyol for DNCB-induced AD-like skin lesions in ICR mice improved scratching behavior and skin severity score. Histological analysis demonstrated that thickening of the skin lesions were significantly reduced in the eriodictyol-treated group. Also, eriodictyol suppressed the DNCB-mediated elevation of IgE serum levels. These results suggest that eriodictyol may be a potential therapeutic resource for AD and an adjunctive agent to control itchiness in AD.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Allergic Agents / therapeutic use*
  • Anti-Inflammatory Agents / therapeutic use*
  • Behavior, Animal / drug effects
  • Dermatitis, Atopic / blood
  • Dermatitis, Atopic / chemically induced
  • Dermatitis, Atopic / drug therapy*
  • Dermatitis, Atopic / pathology
  • Dinitrochlorobenzene
  • Flavanones / therapeutic use*
  • Immunoglobulin E / blood
  • Male
  • Mice
  • Mice, Inbred ICR
  • Pruritus / blood
  • Pruritus / chemically induced
  • Pruritus / drug therapy*
  • Pruritus / pathology
  • Skin / pathology

Substances

  • Anti-Allergic Agents
  • Anti-Inflammatory Agents
  • Dinitrochlorobenzene
  • Flavanones
  • Immunoglobulin E
  • eriodictyol